MP26-04 STANDARDIZED UPTAKE VALUES AS DETERMINED ON PROSTATE-SPECIFIC MEMBRANOUS ANTIGEN POSITRON EMISSION TOMOGRAPHY/COMPUTER TOMOGRAPHY ARE ASSOCIATED WITH GLEASON GRADE AND BIOCHEMICAL RECURREANCE OF DISEASE IN PATIENTS WITH PROSTATE CANCER

You have accessJournal of UrologyProstate Cancer: Detection & Screening II (MP26)1 Sep 2021MP26-04 STANDARDIZED UPTAKE VALUES AS DETERMINED ON PROSTATE-SPECIFIC MEMBRANOUS ANTIGEN POSITRON EMISSION TOMOGRAPHY/COMPUTER TOMOGRAPHY ARE ASSOCIATED WITH GLEASON GRADE AND BIOCHEMICAL RECURREANCE OF DISEASE IN PATIENTS PROSTATE CANCER Yves Bodar, Hans Veerman, Katelijne de Bie, Dennie Meijer, Pim van Leeuwen, Maarten Donswijk, Harry Hendrikse, Ronald Boellaard, Daniela Oprea-Lager, and André Vis BodarYves Bodar More articles by this author , VeermanHans Veerman BieKatelijne Bie MeijerDennie Meijer LeeuwenPim Leeuwen DonswijkMaarten Donswijk HendrikseHarry Hendrikse BoellaardRonald Boellaard Oprea-LagerDaniela Oprea-Lager VisAndré View All Author Informationhttps://doi.org/10.1097/JU.0000000000002023.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION OBJECTIVE: Prostate cancer (PCa) staging has been improved prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PSMA-PET/CT). Intraprostatic PSMA intensity, as measured standardized uptake values (SUV), could predict clinically relevant oncological outcomes for PCa. This study aims investigate the correlation between SUV in patients with PCa prior radical prostatectomy (RP) adverse pathology outcomes, including Gleason score (GS), pN1 status biochemical progression-free survival (PFS). METHODS: A total 318 biopsy-proven scheduled RP a pelvic lymph node dissection 84.5%, (269/318 patients) were retrospectively analysed (median PSA: 10.5 ng/ml). Prior RP, received PET/CT either 68Ga-PSMA (189/318 (59%) or 18F-DCFPyL-PSMA (129/318 (41%) patients). images visually semi-quantitatively measuring maximum (SUVmax) most intense suspect lesion prostate. The SUVmax primary tumour was assessed relation GS, PFS. RESULTS: Patients tumours GS ≤7 showed significantly lower compared >7 both tracers (SUVmax F18: 7.4 versus 14.5; p<0.001, Ga68: 7.3 9.3; p=0.01). Moreover, positive nodes on examination exhibited higher median than those without 7.9 12.3; p=0.04, 7.6 12.0 p<0.001). Of cohort, 77.6% (247/318) free from progression at follow-up 11.6 months (Range 1.4–32.8 months). As shown figure 1, pooled quartiles favourable PFS upper 2 (p<0.001). CONCLUSIONS: PSMA-PET/CT is prognostic may be valuable new biomarker localised correlated intensity tracer accumulation PC tracers. Source Funding: n/a © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e463-e463 Advertisement Copyright Permissions© Inc.MetricsAuthor Information Expand Loading ...